

Creo Medical

Leaner structure, sharper focus

Creo Medical has announced the **disposal** of its in-house manufacturing operations in a management buyout (MBO) transaction, a move strategically aligned with its FY24 repositioning towards a capital-light discovery- and design-focused business. Management expects cost savings of over £1m in FY26, c 15% lower than the FY25 run-rate (FY25 opex of £18.4m; 20% lower than FY24, with Creo delivering £5m in cost savings). We expect this to be directionally positive for Creo, allowing greater management focus on product innovation, regulatory progression and commercial execution. The shift towards a more variable cost base should also improve operational flexibility as the company scales commercial development as procedure volumes increase. We also view the structure of the transaction as favourable (the existing manufacturing team transfers to NewCo), which should help mitigate typical outsourcing risks.

Shift to asset-light model in line with strategy

We see Creo's decision to dispose of its in-house manufacturing operations (transaction expected to close in May 2026) as a logical step aligned with the cost rationalisation and operating model reset outlined in its FY24 results. Structuring the transaction as an MBO enables Creo to transition a fixed-cost function to a variable-cost model while preserving operational continuity. We believe the transfer of the existing manufacturing team (25 full-time employees) alongside the ongoing strategic relationship should help mitigate typical outsourcing risks, particularly around technical expertise and product quality.

Modest upfront savings; upside in the long term

Creo guides to >£1m annual cost savings, a c 15% reduction on the FY25 opex run-rate, already c 20% below FY24 levels. This follows a >40% y-o-y decline in underlying operating losses to £13.3m in FY25, highlighting successful cost discipline. While immediate savings appear modest, we see scope for meaningful operational leverage over the medium term as procedure volumes scale. We believe this should support EBITDA breakeven within the FY28 target, although the longer-term margin impact will depend on undisclosed commercial terms with NewCo and how outsourced costs scale with volume.

Execution key to unlocking profitability pathway

Overall, we view the disposal as a rational step reinforcing Creo's shift towards a capital-light, design- and R&D-led model. The key determinant of the investment case from here will be the group's ability to leverage this leaner structure to drive commercial traction and demonstrate a more clearly defined pathway to profitability.

Historical financials


Year end	Revenue (£m)	PBT (£m)	EPS (p)	P/E (x)	Yield (%)
12/23	4.0	(25.0)	(0.07)	N/A	N/A
12/24	4.0	(27.7)	(0.07)	N/A	N/A
12/25e	6.0	(14.8)	(0.04)	N/A	N/A

Note: The FY25 revenue figure is as reported. PBT and EPS are normalised.

Healthcare
20 April 2026

Price **13.00p**
Market cap **£54m**

Share price performance



Share details

Code	CREO
Listing	AIM
Shares in issue	412.5m
Net cash/(debt) at 31 December 2025	£12.4m

Business description

Creo Medical is a UK-based healthcare company focused on the development and commercialisation of minimally invasive electrosurgical devices. All six products in the flagship CROMA platform are CE marked and FDA cleared. Licensing opportunities for its Kamaptive IP (partnerships with major robotics players such as Intuitive Surgical) offer further monetisation opportunities. In 2025 Creo completed the divestment of a 51% stake in its consumables business to Chinese market leader Micro-Tech.

Bull points

- Positive revenue momentum and utilisation trends.
- Differentiated multi-energy electrosurgical technology platform.
- Partnerships provide validation and optionality.

Bear points

- Early-stage; adoption still developing.
- Potential funding requirements ahead of breakeven.
- Increased reliance on external suppliers with the new capital-light strategy.

Analysts

Jyoti Prakash, CFA	+44 (0)20 3077 5700
Arron Aatkar, PhD	+44 (0)20 3077 5700

healthcare@edisongroup.com

[Edison profile page](#)

EDISON QUICKVIEWS ARE NORMALLY ONE-OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

General disclaimer and copyright

This report has been prepared and issued by Edison. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2026 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
